acyl-CoA dehydrogenase family member 9Genealiases: MC1DN20 · NPD002
Q-omics provides the consensus-scored ACAD9 profile across patient tissues and cancer cell-line models. ACAD9 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ACAD9 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ACAD9 RNA expression shows 19,313 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, COAD, and ACC as cancer lineages where ACAD9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACAD9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACAD9 survival associations across molecular data types. ACAD9 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACAD9 RNA expression–survival associations across cancer types. High ACAD9 expression shows unfavorable associations in LIHC, MESO, KICH, ACC and COAD, but favorable associations in KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ACAD9 RNA expression.
This table summarizes ACAD9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACAD9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACAD9 shows higher tumor expression in COAD, BLCA, LIHC, LUSC, HNSC and CHOL. The COAD box plot shows higher ACAD9 RNA expression in tumor versus normal tissue (log2 FC = +0.716, t-test p < 0.001).
This table shows molecular features associated with ACAD9 in patient tissues and cancer cell lines. In patient samples, ACAD9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACAD9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
